Calgary, Alberta – March 23, 2022 – Universal Ibogaine Inc. (TSXV:IBO and OTCQB: IBOGF) (“UI” or the “Company”) a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, is pleased to announce the key strategic addition of Julie Dumouchel as Director of Clinical Trials. [...]
Calgary, AB – February 28, 2022 – Universal Ibogaine Inc. (TSXV:IBO and OTCQB: IBOGF) (“UI” or the “Company”) a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, is pleased to announce that its common shares have been approved for trading on the OTCQB [...]
Universal Ibogaine and PSQ are pleased to announce the completion of the Qualifying Transaction, closing the $6 million subscription receipt financing.
Universal Ibogaine and PSQ are pleased to announce the completion of the Qualifying Transaction, closing the $6 million subscription receipt financing.
Universal Ibogaine and PSQ are pleased to announce the completion of the Qualifying Transaction, closing the $6 million subscription receipt financing.
Universal Ibogaine and PSQ are pleased to announce the completion of the Qualifying Transaction, closing the $6 million subscription receipt financing.
Universal Ibogaine and PSQ are pleased to announce the completion of the Qualifying Transaction, closing the $6 million subscription receipt financing.
Universal Ibogaine and PSQ are pleased to announce the completion of the Qualifying Transaction, closing the $6 million subscription receipt financing.
Universal Ibogaine and PSQ are pleased to announce the completion of the Qualifying Transaction, closing the $6 million subscription receipt financing.
Universal Ibogaine and PSQ are pleased to announce the completion of the Qualifying Transaction, closing the $6 million subscription receipt financing.
© All rights reserved. • Universal Ibogaine Inc.
